Trial Profile
Randomized Clinical Trial to Evaluate the Efficacy of a Dolutegravir Monotherapy (Tivicay) Versus the Maintenance of a Successful Triple Therapy Using Abacavir + Lamivudine + Dolutegravir (Triumeq) in HIV-1- Infected Patients
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Dolutegravir (Primary) ; Abacavir/dolutegravir/lamivudine
- Indications HIV-1 infections
- Focus Therapeutic Use
- Acronyms MONCAY
- 11 Jul 2019 Results of pooled analysis of data from MONCAY and TRULIGHT trials assessing proportion of participants who had no detectable HIV in genital fluids were published in the Clinical Infectious Diseases.
- 02 Jan 2019 Primary endpoint (Viral Load) has been met, according to the results published in the Clinical Infectious Diseases.
- 02 Jan 2019 Results published in the Clinical Infectious Diseases